Nowadays, guidelines propagate a personalized, multimodal treatment concept. In addition to prescribing drug therapy that is tailored to the severity of COPD, there are numerous other factors that can be used to counteract acute exacerbations and the associated morbidity and mortality risks. This is the subject of numerous studies in which barriers to optimal disease management are identified and strategies are presented to improve the status quo.
Autoren
- Mirjam Peter, M.Sc.
Publikation
- HAUSARZT PRAXIS
Related Topics
You May Also Like
- Chronic Urticaria: Treatment for Patients Unresponsive to Antihistamines
In addition to anti-IgE antibodies, the guideline recommends anti-IL-4α antibodies and BTK inhibition
- Type 1 Diabetes in Childhood
Early Impairment of Glucagon Counterregulation
- Psychosis in Parkinson's Disease
Be Careful When Choosing Medications
- Esophageal Cancer
A Comparison of Endoscopic and Surgical Innovations
- PMR and LVV: Current EULAR Recommendations
Polymyalgia rheumatica, giant cell arteritis, and Takayasu arteritis
- Cellular and Systemic Iron Homeostasis
“Steady State” – a delicately balanced equilibrium
- Psychedelic-assisted therapy
Current status of PAT
- First-line treatment for T2D